Monica Campos dos Santos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Monica Campos dos Santos has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Melissa Orzechowski Xavier
Programa de Pós-Graduação em Ciências da Saúde, Faculdade de Medicina (FAMED), Universidade Federal do Rio Grande (FURG), Rio Grande 96200-190, RS, Brazil
4 shared publications - Vanice Rodrigues Poester
Programa de Pós-Graduação em Ciências da Saúde, Faculdade de Medicina (FAMED), Universidade Federal do Rio Grande (FURG), Rio Grande 96200-190, RS, Brazil
4 shared publications - David A. Stevens
Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
3 shared publications - Mariana Rodrigues Trápaga
Programa de Pós-Graduação em Ciências da Saúde, Faculdade de Medicina (FAMED), Universidade Federal do Rio Grande (FURG), Rio Grande 96200-190, RS, Brazil
3 shared publications - Bianca dos Santos Blan
Programa de Pós-Graduação em Ciências da Saúde, Faculdade de Medicina (FAMED), Universidade Federal do Rio Grande (FURG), Rio Grande 96200-190, RS, Brazil
2 shared publications - Jéssica Estefania Dávila Hidalgo
Programa de Pós-Graduação em Ciências das Saúde, Faculdade de Medicina (FAMED), Universidade Federal do Rio Grande (FURG), Rio Grande 96200-200, RS, Brazil
2 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (10) , 1018
In Vitro Activity of Organoselenium Compounds Against Trichophyton spp.
Background/Objectives: Dermatophytosis is among the most prevalent fungal infections worldwide, and the emergence of antifungal resistance highlights the need for novel the-rapeutic strategies. Organoselenium compounds have demonstrated promising antifungal activity against several pathogenic fungi, although their activity against dermatophytes remains poorly explored. Here we investigate the in vitro antifungal activity of four organoselenium compounds, ebselen, diphenyl diselenide [(PhSe)2], p-methoxy-diphenyl diselenide (BMD), and bis-(3-trifluoromethyl phenyl) diselenide (CF3). Methods: Eighteen clinical isolates belonging to the T. mentagrophytes (n = 10) and T. rubrum (n = 8) species complexes were studied and potential synergism with fluconazole (FCZ) also explored. Antifungal susceptibility testing and drug interaction were performed according to Clinical and Laboratory Standards Institute broth microdilution protocols and checkerboard assay, respectively. Results: Ebselen, (PhSe)2, and BMD inhibited all Trichophyton spp. isolates with a geometric mean (GM) of minimum inhibitory concentration (MIC) less than or equal to 6 µg/mL. CF3 inhibited 78% (14/18) of the isolates and had higher MICs (GM ≥ 43.5 µg/mL). Combination assays revealed synergistic interactions between FCZ and the organoselenium compounds, ranging from 45% to 89%, without antagonistic interactions. Moreover, FCZ activity was enhanced in 57–86% of resistant isolates, with BMD showing the most favorable profile in combination with FCZ. Conclusions: These findings demonstrate the promising antifungal potential of organoselenium compounds against the major dermatophytes associated with human infection and support further investigation of these compounds, particularly ebselen, (PhSe)2, and BMD, as novel antifungal agents, either alone or in combination with conventional antifungal drugs.
- 14 October 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (10) , 1018
Open AccessIn Vitro Activity of Organoselenium Compounds Against Trichophyton spp.
Background/Objectives: Dermatophytosis is among the most prevalent fungal infections worldwide, and the emergence of antifungal resistance highlights the need for novel the-rapeutic strategies. Organoselenium compounds have demonstrated promising antifungal activity against several pathogenic fungi, although their activity against dermatophytes remains poorly explored. Here we investigate the in vitro antifungal activity of four organoselenium compounds, ebselen, diphenyl diselenide [(PhSe)2], p-methoxy-diphenyl diselenide (BMD), and bis-(3-trifluoromethyl phenyl) diselenide (CF3). Methods: Eighteen clinical isolates belonging to the T. mentagrophytes (n = 10) and T. rubrum (n = 8) species complexes were studied and potential synergism with fluconazole (FCZ) also explored. Antifungal susceptibility testing and drug interaction were performed according to Clinical and Laboratory Standards Institute broth microdilution protocols and checkerboard assay, respectively. Results: Ebselen, (PhSe)2, and BMD inhibited all Trichophyton spp. isolates with a geometric mean (GM) of minimum inhibitory concentration (MIC) less than or equal to 6 µg/mL. CF3 inhibited 78% (14/18) of the isolates and had higher MICs (GM ≥ 43.5 µg/mL). Combination assays revealed synergistic interactions between FCZ and the organoselenium compounds, ranging from 45% to 89%, without antagonistic interactions. Moreover, FCZ activity was enhanced in 57–86% of resistant isolates, with BMD showing the most favorable profile in combination with FCZ. Conclusions: These findings demonstrate the promising antifungal potential of organoselenium compounds against the major dermatophytes associated with human infection and support further investigation of these compounds, particularly ebselen, (PhSe)2, and BMD, as novel antifungal agents, either alone or in combination with conventional antifungal drugs.
- Open Access
Severe Multifocal Cutaneous Sporotrichosis Caused by Sporothrix brasiliensis in People Living with HIV in Southern Brazil: Cases and Review
Background: Sporothrix brasiliensis-associated sporotrichosis is an emerging zoonotic mycosis in South America, especially in Brazil. Whereas sporotrichosis is classically described as a lymphangitic disease, multifocal forms occur, predominantly in people living with HIV (PLHIV). We report two cases of severe multifocal cutaneous sporotrichosis caused by S. brasiliensis in PLHIV from a hyperendemic region in southern Rio Grande do Sul, Brazil, and review the relevant literature. Methods and Results: Both patients presented advanced immunosuppression, low CD4+ T-cell counts, and poor adherence to antiretroviral therapy, which contributed to disease progression. The first patient developed recurrent multifocal lesions over a two-year period, whereas the second progressed from extensive mucocutaneous involvement to multifocal disease with partial destruction of nasal cartilage, resulting in permanent sequelae. In both cases, S. brasiliensis was confirmed by culture and species-specific polymerase chain reaction. Isolates from both cases exhibited wild-type susceptibility to itraconazole. Treatment with itraconazole was given, with no susceptibility changes in sequential isolates recovered during disease progression nor after antifungal therapy abandonment. Conclusion: These cases highlight that extensive tissue destruction and permanent deformities, resembling that from other systemic mycoses, can occur in PLHIV. Our findings and review reinforces the importance of early HIV investigation, adherence to antiretroviral and antifungal therapies, and continuous epidemiological and antifungal susceptibility surveillance in hyperendemic regions.
Open AccessSevere Multifocal Cutaneous Sporotrichosis Caused by Sporothrix brasiliensis in People Living with HIV in Southern Brazil: Cases and Review
Background: Sporothrix brasiliensis-associated sporotrichosis is an emerging zoonotic mycosis in South America, especially in Brazil. Whereas sporotrichosis is classically described as a lymphangitic disease, multifocal forms occur, predominantly in people living with HIV (PLHIV). We report two cases of severe multifocal cutaneous sporotrichosis caused by S. brasiliensis in PLHIV from a hyperendemic region in southern Rio Grande do Sul, Brazil, and review the relevant literature. Methods and Results: Both patients presented advanced immunosuppression, low CD4+ T-cell counts, and poor adherence to antiretroviral therapy, which contributed to disease progression. The first patient developed recurrent multifocal lesions over a two-year period, whereas the second progressed from extensive mucocutaneous involvement to multifocal disease with partial destruction of nasal cartilage, resulting in permanent sequelae. In both cases, S. brasiliensis was confirmed by culture and species-specific polymerase chain reaction. Isolates from both cases exhibited wild-type susceptibility to itraconazole. Treatment with itraconazole was given, with no susceptibility changes in sequential isolates recovered during disease progression nor after antifungal therapy abandonment. Conclusion: These cases highlight that extensive tissue destruction and permanent deformities, resembling that from other systemic mycoses, can occur in PLHIV. Our findings and review reinforces the importance of early HIV investigation, adherence to antiretroviral and antifungal therapies, and continuous epidemiological and antifungal susceptibility surveillance in hyperendemic regions.
- 29 May 2026
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 64 (6)
Ocular adnexal sporotrichosis: Case series from a hyperendemic region in southern Brazil
Sporotrichosis is an emerging subcutaneous disease that occurs in outbreaks in Brazil and other South American countries. Reports of extracutaneous cases caused by Sporothrix brasiliensis have been increasing in the literature. This study describes the first case series of ocular adnexal sporotrichosis in the state of Rio Grande do Sul (RS), southern Brazil. A retrospective analysis was conducted, including cases diagnosed over a 3-year period at a specialized reference service in RS, Brazil. Ocular sporotrichosis accounted for 25 cases, with a marked increase observed during the last 2 years of the study (2024–2025), reaching the highest proportion of approximately 16 cases per 100 appointments among all sporotrichosis cases. All patients presented with ocular adnexal involvement, including granulomatous conjunctivitis (56%; 14/25), Parinaud oculoglandular syndrome (40%; 10/25), and eyelid lesions with dacryocystitis in one case (4%). All cases were associated with zoonotic transmission of S. brasiliensis. Clinical cure was achieved using itraconazole (200 mg/day) for a mean treatment duration of 120 days. Our findings highlight the emergence of ocular sporotrichosis in southern Brazil, predominantly affecting adnexal structures, and emphasize the importance of early diagnosis, continuous educational efforts, and increased awareness of extracutaneous manifestations in hyperendemic areas.
- 29 May 2026
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 64 (6)
Ocular adnexal sporotrichosis: Case series from a hyperendemic region in southern Brazil
Sporotrichosis is an emerging subcutaneous disease that occurs in outbreaks in Brazil and other South American countries. Reports of extracutaneous cases caused by Sporothrix brasiliensis have been increasing in the literature. This study describes the first case series of ocular adnexal sporotrichosis in the state of Rio Grande do Sul (RS), southern Brazil. A retrospective analysis was conducted, including cases diagnosed over a 3-year period at a specialized reference service in RS, Brazil. Ocular sporotrichosis accounted for 25 cases, with a marked increase observed during the last 2 years of the study (2024–2025), reaching the highest proportion of approximately 16 cases per 100 appointments among all sporotrichosis cases. All patients presented with ocular adnexal involvement, including granulomatous conjunctivitis (56%; 14/25), Parinaud oculoglandular syndrome (40%; 10/25), and eyelid lesions with dacryocystitis in one case (4%). All cases were associated with zoonotic transmission of S. brasiliensis. Clinical cure was achieved using itraconazole (200 mg/day) for a mean treatment duration of 120 days. Our findings highlight the emergence of ocular sporotrichosis in southern Brazil, predominantly affecting adnexal structures, and emphasize the importance of early diagnosis, continuous educational efforts, and increased awareness of extracutaneous manifestations in hyperendemic areas.
- Open Access
- 2 March 2026
- Published by Microbiology Society in Microbiology
- Vol. 172 (3) , 001663
Antifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens
Background. Natural host defence molecules, part of innate immunity and the first line of defence, are evolutionarily conserved. Some pharmaceutical properties undesirable for clinical use led to the rational design of synthetic molecules with constructed peptide arrangements, giving a novel therapeutic avenue. A prior publication showed synthetic peptide RP557 inhibition and killing of fluconazole-sensitive and resistant Candida species isolates, biofilm inhibition, no resistance induction, direct membrane action, negligible mammalian cell toxicity and topical efficacy in a rodent vaginal candidiasis model. These findings highlight the relevance of investigating RP557 activity against other fungal pathogens. Objective. We evaluated the antifungal spectrum of the RP557 against World Health Organization-listed priority fungal pathogens, including endemic and skin fungal pathogens, both alone and in combination with commercial antifungal drugs. Methods. The antifungal spectrum was evaluated by broth dilution vs. clinical isolates, and we present 76 MICs (mcg ml −1 ) performed according to M27 or M38 CLSI documents, 35 checkerboard interactions with antifungals and 10 minimum fungicidal determinations. Results. Overall impression is robust activity vs. chromoblastomycosis and mycetoma species, Cryptococcus neoformans and Trichophyton spp.; broad MIC ranges within most species, least activity vs. Mucorales and Aspergillus spp.; and some promising drug interactions vs. Sporothrix spp. and Candida auris . Conclusion. Additional efficacy data in vivo is needed. Topical therapy could give local concentrations exceeding MICs, and burn or trauma prophylaxis or treatments are attractive potential targets owing to RP557 panmicrobial properties.
- 2 March 2026
- Published by Microbiology Society in Microbiology
- Vol. 172 (3) , 001663
Open AccessAntifungal activity of the antimicrobial peptide RP557 against priority fungal pathogens
Background. Natural host defence molecules, part of innate immunity and the first line of defence, are evolutionarily conserved. Some pharmaceutical properties undesirable for clinical use led to the rational design of synthetic molecules with constructed peptide arrangements, giving a novel therapeutic avenue. A prior publication showed synthetic peptide RP557 inhibition and killing of fluconazole-sensitive and resistant Candida species isolates, biofilm inhibition, no resistance induction, direct membrane action, negligible mammalian cell toxicity and topical efficacy in a rodent vaginal candidiasis model. These findings highlight the relevance of investigating RP557 activity against other fungal pathogens. Objective. We evaluated the antifungal spectrum of the RP557 against World Health Organization-listed priority fungal pathogens, including endemic and skin fungal pathogens, both alone and in combination with commercial antifungal drugs. Methods. The antifungal spectrum was evaluated by broth dilution vs. clinical isolates, and we present 76 MICs (mcg ml −1 ) performed according to M27 or M38 CLSI documents, 35 checkerboard interactions with antifungals and 10 minimum fungicidal determinations. Results. Overall impression is robust activity vs. chromoblastomycosis and mycetoma species, Cryptococcus neoformans and Trichophyton spp.; broad MIC ranges within most species, least activity vs. Mucorales and Aspergillus spp.; and some promising drug interactions vs. Sporothrix spp. and Candida auris . Conclusion. Additional efficacy data in vivo is needed. Topical therapy could give local concentrations exceeding MICs, and burn or trauma prophylaxis or treatments are attractive potential targets owing to RP557 panmicrobial properties.